

Liliane Tenenbaum

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9393149/publications.pdf>

Version: 2024-02-01

55
papers

2,187
citations

257101

24
h-index

233125

45
g-index

56
all docs

56
docs citations

56
times ranked

2984
citing authors

#	ARTICLE	IF	CITATIONS
1	Tet-On Systems For Doxycycline-inducible Gene Expression. <i>Current Gene Therapy</i> , 2016, 16, 156-167.	0.9	253
2	Recombinant AAV-mediated gene delivery to the central nervous system. <i>Journal of Gene Medicine</i> , 2004, 6, S212-S222.	1.4	180
3	Clinical potential of minocycline for neurodegenerative disorders. <i>Neurobiology of Disease</i> , 2004, 17, 359-366.	2.1	145
4	Evaluation of Risks Related to the Use of Adeno-Associated Virus-Based Vectors. <i>Current Gene Therapy</i> , 2003, 3, 545-565.	0.9	132
5	Characterization of a Recombinant Adeno-Associated Virus Type 2 Reference Standard Material. <i>Human Gene Therapy</i> , 2010, 21, 1273-1285.	1.4	125
6	Rescue and sprouting of motoneurons following ventral root avulsion and reimplantation combined with intraspinal adeno-associated viral vector-mediated expression of glial cell line-derived neurotrophic factor or brain-derived neurotrophic factor. <i>Experimental Neurology</i> , 2004, 189, 303-316.	2.0	119
7	Regulated viral BDNF delivery in combination with Schwann cells promotes axonal regeneration through capillary alginate hydrogels after spinal cord injury. <i>Acta Biomaterialia</i> , 2017, 60, 167-180.	4.1	93
8	Tetracycline-inducible transgene expression mediated by a single AAV vector. <i>Gene Therapy</i> , 2003, 10, 84-94.	2.3	91
9	Manufacturing and Characterization of a Recombinant Adeno-Associated Virus Type 8 Reference Standard Material. <i>Human Gene Therapy</i> , 2014, 25, 977-987.	1.4	80
10	Biosafety of Recombinant Adeno-associated Virus Vectors. <i>Current Gene Therapy</i> , 2014, 13, 434-452.	0.9	77
11	MMP9/RAGE pathway overactivation mediates redox dysregulation and neuroinflammation, leading to inhibitory/excitatory imbalance: a reverse translation study in schizophrenia patients. <i>Molecular Psychiatry</i> , 2020, 25, 2889-2904.	4.1	76
12	A system for detection of genetic and epigenetic alterations in <i>Escherichia coli</i> induced by DNA-damaging agents. <i>Journal of Molecular Biology</i> , 1985, 186, 97-105.	2.0	59
13	GDNF, A Neuron-Derived Factor Upregulated in Glial Cells during Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 456.	1.0	53
14	Minocycline in phenotypic models of Huntington's disease. <i>Neurobiology of Disease</i> , 2005, 18, 206-217.	2.1	52
15	Development of a Liver-specific Tet-On Inducible System for AAV Vectors and Its Application in the Treatment of Liver Cancer. <i>Molecular Therapy</i> , 2011, 19, 1245-1253.	3.7	51
16	Glial Cell Line-Derived Neurotrophic Factor Gene Delivery in Parkinson's Disease: A Delicate Balance between Neuroprotection, Trophic Effects, and Unwanted Compensatory Mechanisms. <i>Frontiers in Neuroanatomy</i> , 2017, 11, 29.	0.9	51
17	Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector. <i>Experimental Neurology</i> , 2007, 204, 387-399.	2.0	47
18	Tropism of AAV-2 vectors for neurons of the globus pallidus. <i>NeuroReport</i> , 2000, 11, 2277-2283.	0.6	38

#	ARTICLE	IF	CITATIONS
19	Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model. <i>Journal of Gene Medicine</i> , 2009, 11, 899-912.	1.4	37
20	Mild guanidinoacetate increase under partial guanidinoacetate methyltransferase deficiency strongly affects brain cell development. <i>Neurobiology of Disease</i> , 2015, 79, 14-27.	2.1	37
21	Use of an autonomous parvovirus vector for selective transfer of a foreign gene into transformed human cells of different tissue origins and its expression therein. <i>Journal of Virology</i> , 1994, 68, 1397-1406.	1.5	37
22	A regulatable AAV vector mediating GDNF biological effects at clinically-approved sub-antimicrobial doxycycline doses. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16027.	1.8	32
23	A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 217-232.	1.1	28
24	Cellular contaminants of adeno-associated virus vector stocks can enhance transduction. <i>Gene Therapy</i> , 1999, 6, 1045-1053.	2.3	26
25	Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 273-281.	2.0	25
26	Neuroprotective gene therapy for Parkinson's disease. <i>Current Gene Therapy</i> , 2002, 2, 451-483.	0.9	23
27	Long-term controlled GDNF over-expression reduces dopamine transporter activity without affecting tyrosine hydroxylase expression in the rat mesostriatal system. <i>Neurobiology of Disease</i> , 2016, 88, 44-54.	2.1	20
28	Rapid Transgene Expression in Multiple Precursor Cell Types of Adult Rat Subventricular Zone Mediated by Adeno-Associated Type 1 Vectors. <i>Human Gene Therapy</i> , 2012, 23, 742-753.	1.4	17
29	Human Fetal Cell Therapy in Huntington's Disease: A Randomized, Multicenter, Phase II Trial. <i>Movement Disorders</i> , 2020, 35, 1323-1335.	2.2	16
30	Minocycline-induced activation of tetracycline-responsive promoter. <i>Neuroscience Letters</i> , 2003, 352, 155-158.	1.0	15
31	Differential Transgene Expression Profiles in Rat Brain, Using rAAV2/1 Vectors with Tetracycline-Inducible and Cytomegalovirus Promoters. <i>Human Gene Therapy</i> , 2008, 19, 1293-1306.	1.4	15
32	Combining Gene Transfer and Nonhuman Primates to Better Understand and Treat Parkinson's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 10.	1.4	14
33	Inhibition of Heterologous DNA Replication by the MVMP Nonstructural NS-1 Protein: Identification of a Target Sequence. <i>Virology</i> , 1993, 197, 630-641.	1.1	13
34	Genotoxic potency of monofunctional alkylating agents in E. coli: comparison with carcinogenic potency in rodents. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1990, 228, 177-185.	0.4	12
35	Plastic phenotype of human oligodendroglial tumour cells in vitro. <i>Neuropathology and Applied Neurobiology</i> , 1996, 22, 302-310.	1.8	12
36	recA-independent mutagenicity induced by chloroethylene oxide in E. coli. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1985, 152, 157-159.	0.4	10

#	ARTICLE	IF	CITATIONS
37	Recombinant AAV Delivery to the Central Nervous System. <i>Methods in Molecular Biology</i> , 2012, 807, 159-177.	0.4	10
38	AAV2 vectors mediate efficient and sustained transduction of rat embryonic ventral mesencephalon. <i>NeuroReport</i> , 2002, 13, 1503-1507.	0.6	9
39	An Adeno-Associated Virus-Based Intracellular Sensor of Pathological Nuclear Factor- κ B Activation for Disease-Inducible Gene Transfer. <i>PLoS ONE</i> , 2013, 8, e53156.	1.1	9
40	The E. coli multitest: a set of strains to characterize diverse genotoxic effects. <i>Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology</i> , 1988, 203, 415-426.	0.4	7
41	Intracisternal delivery of NF- κ B-inducible scAAV2/9 reveals locoregional neuroinflammation induced by systemic kainic acid treatment. <i>Frontiers in Molecular Neuroscience</i> , 2014, 7, 92.	1.4	7
42	Recombinant AAV Viral Vectors Serotype 1, 2, and 5 Mediate Differential Gene Transfer Efficiency in Rat Striatal Fetal Grafts. <i>Cell Transplantation</i> , 2007, 16, 1013-1020.	1.2	6
43	Efficient Early and Sustained Transduction of Human Fetal Mesencephalon Using Adeno-Associated Virus Type 2 Vectors. <i>Cell Transplantation</i> , 2004, 13, 565-572.	1.2	5
44	Selective targeting of striatal parvalbumin-expressing interneurons for transgene delivery. <i>Journal of Neuroscience Methods</i> , 2021, 354, 109105.	1.3	5
45	Recombinant AAV viral vectors serotype 1, 2, and 5 mediate differential gene transfer efficiency in rat striatal fetal grafts. <i>Cell Transplantation</i> , 2008, 16, 1013-20.	1.2	4
46	Quantification of the genotoxic effects of alkylating agents in bacterial assays. <i>Mutagenesis</i> , 1988, 3, 317-322.	1.0	3
47	Efficiency of adeno-associated virus type-2 vectors in non-human primate Schwann cells. <i>NeuroReport</i> , 2005, 16, 1757-1762.	0.6	3
48	Effect of SOCS1 overexpression on RPE cell activation by proinflammatory cytokines. <i>Neuroscience Letters</i> , 2016, 630, 209-215.	1.0	2
49	Virus Vectors for use in the Central Nervous System. <i>International Review of Neurobiology</i> , 2003, 55, 65-98.	0.9	1
50	Overexpression of mouse IsK protein fused to green fluorescent protein induces apoptosis of human astrogloma cells. <i>Neurological Research</i> , 2007, 29, 628-631.	0.6	1
51	59.2 Matrix Metalloproteinase Inhibition Prevents the Adult Excitatory-Inhibitory Imbalance Induced by the Reciprocal Interaction Between Neuroinflammation and Oxidative Stress During Development. <i>Schizophrenia Bulletin</i> , 2017, 43, S32-S32.	2.3	1
52	CDNF: An innovative actor in disease-modifying approaches for Parkinson's disease. <i>Molecular Therapy</i> , 2021, 29, 2634-2636.	3.7	1
53	Differential transgene expression profiles from rAAV2/1 vectors using the tetON and CMV promoters in the rat brain.. <i>Human Gene Therapy</i> , 2008, .	1.4	1
54	243. Control of Undesirable Effects of GDNF Delivered in the Striatum of Healthy Rats Using a Tetracycline-Inducible AAV1 Vector. <i>Molecular Therapy</i> , 2006, 13, S93.	3.7	0

#	ARTICLE	IF	CITATIONS
55	610. An Inducible AAV Vector Mediating GDNF Signal Transduction at Clinically-Acceptable Sub-Antimicrobial Doxycycline Doses. <i>Molecular Therapy</i> , 2016, 24, S242.	3.7	0